Biogen (BIIB) Stock Price, News & Analysis

Company Overview

Biogen Inc. is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia. The company also partnered with Eisai on Leqembi (lecanemab), an Alzheimer’s disease treatment, and has participated in the development and commercialization of biosimilars through its collaboration with Samsung Bioepis.

Founded in 1978, Biogen is headquartered in Cambridge, Massachusetts, and serves patients and healthcare providers in markets around the world. The company’s operations include research and development, regulatory support, manufacturing and commercial activities across North America, Europe and other international regions. Biogen is led by Chief Executive Officer Christopher A. Viehbacher.

Key Stats

• Today's Range: $215.73 to $223.09
• 50-Day Range: $201.82 to $228.69
• 52-Week Range: $138.00 to $230.49
• Volume: 1.34 million shs
• Average Volume: 1.14 million shs
• Market Capitalization: $32.27 billion
• P/E Ratio: 38.66
• Dividend Yield: N/A
• Price Target: $230.00
• Consensus Rating: Moderate Buy

Biogen Stock Analysis - MarketRank™

Biogen scored higher than 67% of companies evaluated by MarketBeat, and ranked 370th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Biogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 1 strong buy rating, 17 buy ratings, 13 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Biogen is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Biogen has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 29.81%

Earnings Growth

Earnings for Biogen are expected to grow by 29.81% in the coming year, from $12.41 to $16.11 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biogen is 38.66, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.55.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biogen is 38.66, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.55.

Price to Earnings Growth Ratio

Biogen has a PEG Ratio of 2.45. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Biogen has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.95% of the float of Biogen has been sold short.

Short Interest Ratio / Days to Cover

Biogen has a short interest ratio ("days to cover") of 7.59.

Change versus previous month

Short interest in Biogen has recently increased by 1.59%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biogen does not currently pay a dividend.

Dividend Growth

Biogen does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.74

News Sentiment

Biogen has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Biogen this week, compared to 11 articles on an average week.

Search Interest

20 people have searched for BIIB on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biogen insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.25% of the stock of Biogen is held by insiders.

Percentage Held by Institutions

87.93% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 10/08/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BIIB
• CIK: 875045
• Web: www.biogen.com
• Phone: (617) 679-2000
• Fax: 617-679-2617
• Employees: 7,500
• Year Founded: 1978

Price Target and Rating

• Average Price Target for Biogen: $230.00
• High Price Target: $300.00
• Low Price Target: $175.00
• Potential Upside/Downside: +5.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 32 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.65
• Trailing P/E Ratio: 38.66
• Forward P/E Ratio: 17.60
• P/E Growth: 2.45
• Net Income: $1.29 billion
• Net Margins: 8.32%
• Pretax Margin: 10.09%
• Return on Equity: 11.18%
• Return on Assets: 6.88%

Debt

• Debt-to-Equity Ratio: 0.39
• Current Ratio: 1.87
• Quick Ratio: 1.26

Sales & Book Value

• Annual Sales: $9.89 billion
• Price / Sales: 3.26
• Cash Flow: $22.27 per share
• Price / Cash Flow: 9.81
• Book Value: $124.45 per share
• Price / Book: 1.76

Miscellaneous

• Outstanding Shares: 147,750,000
• Free Float: 147,385,000
• Market Cap: $32.27 billion
• Optionable: Optionable
• Beta: 0.09